✦ LIBER ✦

Drug development risk in HIV-1 clinical trials: the effect of drug class

✍ Scribed by Brendan J.W. Osborne; Rupert Kaul; Jayson L. Parker

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Capturing patients' perspectives of trea

✍ Asha Hareendran; Ari Gnanasakthy; Randall Winnette; Dennis Revicki 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 179 KB

Risk of clinically significant depressio

✍ Gutiérrez, F; García, L; Padilla, S; Álvarez, D; Moreno, S; Navarro, G; Gómez-Si 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

Transmission of triple-class, drug-resis

✍ W. W. Y. Tong; J. McAllister; P. A. White; A. D. Kelleher; A. Carr 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

The future of drug development: advancin

✍ Orloff, John; Douglas, Frank; Pinheiro, Jose; Levinson, Susan; Branson, Michael; 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 758 KB

HIV-1 Drug Resistance in the iPrEx Preex

✍ Liegler, T.; Abdel-Mohsen, M.; Bentley, L. G.; Atchison, R.; Schmidt, T.; Javier 📂 Article 📅 2014 🏛 University of Chicago Press 🌐 English ⚖ 961 KB

The role of clinical trials in drug regu

✍ Ursula Gundert-Remy 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 316 KB